TY - JOUR
T1 - Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry – A tutorial
AU - El Amrani, Mohsin
AU - Donners, Anouk A.M.
AU - Hack, C. Erik
AU - Huitema, Alwin D.R.
AU - van Maarseveen, Erik M.
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/11/8
Y1 - 2019/11/8
N2 - The promising pipeline of therapeutic monoclonal antibodies (mAbs) demands robust bioanalytical methods with swift development times for pharmacokinetic studies. Over the past decades ligand binding assays were the methods of choice for absolute quantification. However, the production of the required anti-idiotypic antibodies and ligands limits high-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic mAbs. In recent years, high-resolution liquid chromatography tandem mass-spectrometry (LC-MS) systems have enabled absolute quantification of therapeutic mAbs with short method development times. These systems have additional benefits, such as a large linear dynamic range, a high specificity and the option of multiplexing. Here, we briefly discuss the current strategies for the quantification of therapeutic mAbs in biological matrices using LC-MS analysis based on top-down and middle-down quantitative proteomics. Then, we present the widely used bottom-up method in a six-step workflow, which can be used as guidance for quantitative LC-MS/MS method development of mAbs. Finally, strengths and weaknesses of the bottom-up method, which currently provides the most benefits, are discussed in detail.
AB - The promising pipeline of therapeutic monoclonal antibodies (mAbs) demands robust bioanalytical methods with swift development times for pharmacokinetic studies. Over the past decades ligand binding assays were the methods of choice for absolute quantification. However, the production of the required anti-idiotypic antibodies and ligands limits high-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic mAbs. In recent years, high-resolution liquid chromatography tandem mass-spectrometry (LC-MS) systems have enabled absolute quantification of therapeutic mAbs with short method development times. These systems have additional benefits, such as a large linear dynamic range, a high specificity and the option of multiplexing. Here, we briefly discuss the current strategies for the quantification of therapeutic mAbs in biological matrices using LC-MS analysis based on top-down and middle-down quantitative proteomics. Then, we present the widely used bottom-up method in a six-step workflow, which can be used as guidance for quantitative LC-MS/MS method development of mAbs. Finally, strengths and weaknesses of the bottom-up method, which currently provides the most benefits, are discussed in detail.
KW - LC-MS/MS
KW - Method development
KW - Quantitative proteomics
KW - Sample purification
KW - Therapeutic monoclonal antibodies
KW - Trypsin digestion
UR - http://www.scopus.com/inward/record.url?scp=85067199565&partnerID=8YFLogxK
U2 - 10.1016/j.aca.2019.05.076
DO - 10.1016/j.aca.2019.05.076
M3 - Review article
C2 - 31409472
AN - SCOPUS:85067199565
SN - 0003-2670
VL - 1080
SP - 22
EP - 34
JO - Analytica Chimica Acta
JF - Analytica Chimica Acta
ER -